- For Many in US, It Will Be a Scaled-Down Holiday Season
- US Bonds Pare Losses After 7-Year Auction
- New-Home Sales Jump to Highest Level in Over Year
- Judge Erases Couple's $525,000 Mortgage Payment
- Claims Level Suggests End to Job Losses
- Consumers Catching the Holiday Spirit
- Activision Prepares to Double Dip on ‘Modern Warfare 2’
- Airlines Hit With Penalties for Stranding Passengers
- Garlic Price Rises Surpass Gold, Stocks in China
- Consumers Catching the Holiday Spirit
- It's Beginning To Look A Lot More Riskless
- Crescenzi: Claims Level Suggests End to Job Losses
- Hedge Funds Take Early Lead in Warren Buffett's 'Big Bet'
- S&P Stocks Trading at New 52-Week Highs
- 4 Food Stocks to Stuff in Your Portfolio: Analyst
- S&P at 1050-1200 Trading Range Next Year: Strategist
- Treasury On Mortgage Modifications
- Blue Jeans Expected to See Another Green Christmas
MOST SHARED
- Ritz-Carlton ?Struggling? in the US: President
- Garlic Price Rises Surpass Gold, Stocks in China
- New-Home Sales Jump 6.2% To Highest Level in Over Year
- Half of Banks' Losses May Still Be Hidden: IMF Head
- Oil Price to Average $75.40 in 2010: Poll
- S&P Stocks Trading at New 52-Week Highs
- Americans Ditch Planes for Trains this Thanksgiving
- Consumer Mood Improves, But Anxiety Over Personal Finances
- Jobless Claims Below 500,000, Durable Orders Slip
Text Size 
LONDON, Oct 29 (Reuters) - European regulators reported another case of potentially deadly brain infection in patients taking multiple sclerosis drug Tysabri, taking the worldwide total since 2006 to 24. There have been four deaths, a spokeswoman for the European Medicines Agency said on Thursday. The European Union accounts for 14 of the cases of progressive multifocal leukoencephalopathy (PML), with two in Switzerland and eight in the United States. Last Friday, the agency announced it had begun a review of the drug after reports of 23 cases of PML, sending shares in the drug's makers Biogen Idec Inc and Elan Corp Plc sharply lower. Tysabri was temporarily withdrawn from the market in 2005 after being linked with the disease. It was reintroduced in July 2006 with stricter safety warnings. Elan fell as much as 3 percent to a new year low on Thursday, before recovering, while Biogen was down 0.7 percent by 1615 GMT. (Reporting by Ben Hirschler; Editing by David Cowell) Keywords: ELAN BIOGEN/ (ben.hirschler@thomsonreuters.com; Tel: +44 20 7542 5082; Reuters Messaging: ben.hirschler.reuters.com@reuters.net; www.twitter.com/reutersBenHir) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
Print
Email
- Here's how key provisions of the health care reform bill would impact your insurance and how you'll pay for it.
- Remember when auto shows were major events where new models could generate buzz?
- It may be the most unusual guide to business you'll read.
- After nine years the NBA’s minor league equivalent is finally coming into its own.
- Bill Griffeth is taking a leave of absence from CNBC and Power Lunch for a year. Here's a message from Bill.
- For nearly three decades, these on-call experts have been dishing advice on how to – and not to – cook turkey.
Data is a real-time snapshot *Data is delayed at least 15 minutes